Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Gabriel Fernandes-Silva, Mayara Ivani de Paula & Érika B. Rangel. (2017) mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions. Expert Opinion on Drug Metabolism & Toxicology 13:4, pages 367-385.
Read now
Read now
Markus van der Giet, Josep M Cruzado, Johan W de Fijter, Hallvard Holdaas, Zailong Wang, Antonio Speziale & Guido Junge. (2014) ELEVATE: an innovative study design to assess the efficacy, safety, and evolution of cardiovascular parameters in de novo kidney transplant recipients after early conversion from a calcineurin inhibitor to everolimus. Open Access Journal of Clinical Trials 6, pages 17-27.
Read now
Read now
Ignacio Duran, Peter-Jürgen Goebell, Konstantinos Papazisis, Alain Ravaud, Thomas Weichhart, Jose Antonio Rodriguez-Portal & Klemens Budde. (2014) Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. Expert Opinion on Drug Safety 13:3, pages 361-372.
Read now
Read now
Articles from other publishers (22)
Jiawen Liu, Dengyuan Feng, Xuechun Kan, Ming Zheng, Xiang Zhang, Zijie Wang, Li Sun, Hao Chen, Xiang Gao, Ting Lu, Min Gu, Ruoyun Tan & Zhijian Han. (2021)
Polymorphisms in the
CYP3A5
gene significantly affect the pharmacokinetics of sirolimus after kidney transplantation
. Pharmacogenomics 22:14, pages 903-912.
Crossref
Crossref
Hong Yu, Solomiya Nysak, Noemi Garg, Edison Ong, Xianwei Ye, Xiangyan Zhang & Yongqun He. (2019) ODAE: Ontology-based systematic representation and analysis of drug adverse events and its usage in study of adverse events given different patient age and disease conditions. BMC Bioinformatics 20:S7.
Crossref
Crossref
. Experimental and Clinical Transplantation 16:3.
Crossref
Crossref
Oscar Rodríguez Faba, Romain Boissier, Klemens Budde, Arnaldo Figueiredo, Claire Fraser Taylor, Vital Hevia, Enrique Lledó García, Heinz Regele, Rhana Hassan Zakri, Jonathon Olsburgh & Alberto Breda. (2018) European Association of Urology Guidelines on Renal Transplantation: Update 2018. European Urology Focus 4:2, pages 208-215.
Crossref
Crossref
M. Dürr, N. Lachmann, B. Zukunft, D. Schmidt, K. Budde & S. Brakemeier. (2017) Late Conversion to Belatacept After Kidney Transplantation: Outcome and Prognostic Factors. Transplantation Proceedings 49:8, pages 1747-1756.e1.
Crossref
Crossref
Xiaofan Ma, Jianping Yao, Yuan Yue, Shangming Du, Han Qin, Jian Hou & Zhongkai Wu. (2017) Rapamycin reduced pulmonary vascular remodelling by inhibiting cell proliferation via Akt/mTOR signalling pathway down-regulation in the carotid artery–jugular vein shunt pulmonary hypertension rat model. Interactive CardioVascular and Thoracic Surgery 25:2, pages 206-211.
Crossref
Crossref
Angela W.S. Fung, Michael J. Knauer, Ivan M. Blasutig, David A. Colantonio & Vathany Kulasingam. (2017) Evaluation of electrochemiluminescence immunoassays for immunosuppressive drugs on the Roche cobas e411 analyzer. F1000Research 6, pages 1832.
Crossref
Crossref
Oleg O. Rummo, Mario Carmellini, Lionel Rostaing, Rainer Oberbauer, Maarten H. L. Christiaans, Christiane Mousson, Robert M. Langer, Franco Citterio, Bernard Charpentier, Malcolm Brown, Gbenga Kazeem & Frank Lehner. (2017)
ADHERE: randomized controlled trial comparing renal function in
de novo
kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus
. Transplant International 30:1, pages 83-95.
Crossref
Crossref
Jamal Bamoulid, Oliver Staeck, Fabian Halleck, Dmytri Khadzhynov, Alexander Paliege, Susanne Brakemeier, Michael Dürr & Klemens Budde. (2016) Immunosuppression and Results in Renal Transplantation. European Urology Supplements 15:9, pages 415-429.
Crossref
Crossref
Susanne Brakemeier, Dennis Kannenkeril, Michael Dürr, Tobias Braun, Friederike Bachmann, Danilo Schmidt, Michael Wiesener & Klemens Budde. (2016) Experience with belatacept rescue therapy in kidney transplant recipients. Transplant International 29:11, pages 1184-1195.
Crossref
Crossref
Matthias Waldner, Daniel Fantus, Mario Solari & Angus W. Thomson. (2016) New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation. British Journal of Clinical Pharmacology 82:5, pages 1158-1170.
Crossref
Crossref
Daniel Fantus, Natasha M. Rogers, Florian Grahammer, Tobias B. Huber & Angus W. Thomson. (2016) Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. Nature Reviews Nephrology 12:10, pages 587-609.
Crossref
Crossref
Stein Bergan, Sara Bremer & Nils Tore Vethe. (2016) Drug target molecules to guide immunosuppression. Clinical Biochemistry 49:4-5, pages 411-418.
Crossref
Crossref
Juhan LeeSeung Hwan SongJae Geun LeeBeom Seok KimKyu Ha HuhYu Seun Kim. (2016) Sirolimus Combination with Tacrolimus in Kidney Transplant Recipients at High Immunological Risk: Observational Results 3 Years after Transplantation. The Journal of the Korean Society for Transplantation 30:4, pages 165.
Crossref
Crossref
Jurjen Zandstra, Marike M. van Beuge, Johan Zuidema, Arjen H. Petersen, Mark Staal, Luisa F. Duque, Sergio Rodriguez, Audrey A. R. Lathuile, Gert J. Veldhuis, Rob Steendam, Ruud A. Bank & Eliane R. Popa. (2015) Microsphere-Based Rapamycin Delivery, Systemic Versus Local Administration in a Rat Model of Renal Ischemia/Reperfusion Injury. Pharmaceutical Research 32:10, pages 3238-3247.
Crossref
Crossref
Jamal Bamoulid, Oliver Staeck, Fabian Halleck, Dmytri Khadzhynov, Susanne Brakemeier, Michael Dürr & Klemens Budde. (2015) The need for minimization strategies: current problems of immunosuppression. Transplant International 28:8, pages 891-900.
Crossref
Crossref
Klemens Budde, Claudia Sommerer, Thomas Rath, Petra Reinke, Hermann Haller, Oliver Witzke, Barbara Suwelack, Daniel Baeumer, Christian Sieder, Martina Porstner & Wolfgang Arns. (2014) Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial. Journal of Nephrology 28:1, pages 115-123.
Crossref
Crossref
Alfredo J. Lucendo & Javier Molina-Infante. (2013) Emerging Therapeutic Strategies for Eosinophilic Esophagitis. Current Treatment Options in Gastroenterology 12:1, pages 1-17.
Crossref
Crossref
Marcel G. Naik, Katharina M. Heller, Wolfgang Arns, Klemens Budde, Fritz Diekmann, Frank Eitner, Michael Fischereder, Jan Goßmann, Nils Heyne, Christian Morath, Udo Riester, Wilfried Gwinner & Jan Steffen Jürgensen. (2014) Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter database. Clinical Transplantation 28:1, pages 67-79.
Crossref
Crossref
K. Stein, M. Maruschke, C. Protzel & O.W. Hakenberg. (2014) Allogene NierentransplantationAllogeneic kidney transplantation. Der Urologe 53:1, pages 91-102.
Crossref
Crossref
F. Halleck, F. Friedersdorff, T.F. Fuller, M. Matz, L. Huber, M. Dürr, M. Schütz & K. Budde. (2013) New Perspectives of Immunosuppression. Transplantation Proceedings 45:3, pages 1224-1231.
Crossref
Crossref
Fabian Halleck & Klemens Budde. (2012) Sirolimus for secondary SCC prevention in renal transplantation. Nature Reviews Nephrology 8:12, pages 687-689.
Crossref
Crossref